Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical
company focused on developing and commercializing first-in-class, oral
low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies
for the treatment of hypercholesterolemia and other cardiometabolic risk
markers, today provided ETC-1002 development program updates and
financial results for the third quarter ended September 30, 2014.
for Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Third Quarter 2014 Financial Results investment picks